Q2 2012

Oxea, a global supplier of Oxo Intermediates and Oxo Derivatives, today announced robust earnings for the second quarter of 2012, with net sales of €380 million getting close to prior year's level.

News

Saudi Basic Industries Q2 Profits Fall 35%

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

20 Years of CHEManager International

Nova-Institut GmbH

Advanced Recycling Conference 2025: New Paths to the Circular Economy

CHEManager International c/o Wiley-VCH GmbH

Brenntag Downsizes Management Board, Retains Both Divisions

Hamilton Bonaduz AG

Optimize Your Process with Smart Oxygen Sensors for Inertization and Blanketing Applications

Concept Heidelberg

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Interview

Strategic Response to a Shifting Pharma Landscape

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Oxea